Reduced ZHX2 and ZHX3 expression was remarkably correlated with a longer survival time in the subgroups of GC patients without lymph node metastases or distant metastasis, suggesting that the low expression of ZHX2 and ZHX3 predicts a better prognosis for early-stage gastric cancer patients. The gene discussed is ZHX3; the disease is metastatic malignant neoplasm in the lymph nodes.